Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit

Rhea-AI Summary

Pandion Therapeutics (Nasdaq: PAND) announced that CEO Rahul Kakkar will participate in a panel discussion at the Stifel Immunology & Inflammation Summit on October 1, 2020, at 3:00 p.m. ET. A live audio webcast of the discussion will be available on the company's investor website, with a replay accessible after the event.

Pandion focuses on developing novel therapeutics for autoimmune diseases, utilizing its TALON platform. Its lead product candidate, PT101, is currently undergoing a Phase 1a clinical trial, aimed at expanding regulatory T cells without activating pro-inflammatory cells.

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a panel discussion at the upcoming Stifel Immunology & Inflammation Summit on Thursday, October 1, 2020 at 3:00 p.m. ET.

A live audio webcast of the panel will be available on the Investors and News section of Pandion Therapeutics’ investor website at https://investors.pandiontx.com/. A replay of the webcast will be available shortly following the presentation.

About Pandion Therapeutics
Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells, is currently in a Phase 1a clinical trial. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com.

For further information, please contact:

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors:
Michelle Avery
Pandion Therapeutics
investors@pandiontx.com 

FAQ

When will Pandion Therapeutics CEO participate in the Stifel Immunology Summit?

CEO Rahul Kakkar of Pandion Therapeutics will participate in a panel discussion on October 1, 2020, at 3:00 p.m. ET.

Where can I watch the Pandion Therapeutics panel discussion?

The panel discussion can be viewed via a live audio webcast on the Investors and News section of Pandion Therapeutics’ investor website.

What is the focus of Pandion Therapeutics?

Pandion Therapeutics is focused on developing novel therapeutics to address unmet needs in patients with autoimmune diseases.

What is PT101 from Pandion Therapeutics?

PT101 is Pandion's lead product candidate designed to selectively expand regulatory T cells while avoiding activation of pro-inflammatory cells, currently in Phase 1a clinical trials.